Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 16/20 | 0.80 |
| ▸ | HTR2C | P28335 | 11/20 | 0.80 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5651122 | 0.91 | MCHR1 (0.76) | MCHR1HTR2CACKR3 | |
| SCHEMBL5645850 | 0.91 | MCHR1 (0.79) | MCHR1HTR2CACKR3 | |
| SCHEMBL5649494 | 0.90 | MCHR1 (0.77) | MCHR1HTR2CACKR3HDAC1 | |
| SCHEMBL5647203 | 0.90 | MCHR1 (0.77) | MCHR1HTR2CACKR3 | |
| SCHEMBL5646746 | 0.90 | MCHR1 (0.81) | MCHR1HTR2CACKR3 | |
| SCHEMBL5644487 | 0.89 | MCHR1 (0.75) | MCHR1HTR2CACKR3HDAC1 | |
| SCHEMBL5646824 | 0.89 | MCHR1 (0.75) | MCHR1HTR2CACKR3 | |
| SCHEMBL5647406 | 0.89 | MCHR1 (1.00) | MCHR1HTR2CHDAC1 | |
| SCHEMBL5645067 | 0.88 | MCHR1 (0.74) | MCHR1HTR2CACKR3HDAC1 | |
| SCHEMBL5649184 | 0.88 | MCHR1 (0.98) | MCHR1HTR2CHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183415-B2 | Quinoline compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-7183415-B2 | Quinoline compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-7183415-B2 | Quinoline compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20050209213-A1 | Quinoline compound | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1447402-A1 | QUINOLINE COMPOUND | Takeda Chemical Industries, Ltd. (JP) | 2004-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209213-A1 | Quinoline compound | MC1R, MC2R, TYR | MCHR1 4/4885HTR2C 36/4885ACKR3 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.